Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference
Acadia Pharmaceuticals Inc. announced it will present two data presentations related to Alzheimer's disease psychosis (ADP) and its investigational drug, remlifanserin, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. The presentations will include findings from the Phase 2 portion of the ongoing RADIANT clinical trial program, which evaluates remlifanserin in patients with ADP. An oral presentation will detail the efficacy and safety of remlifanserin, while a poster presentation will examine biomarker heterogeneity among patients meeting clinical criteria for ADP. Remlifanserin is a novel, highly selective 5-HT2A receptor inverse agonist being developed to treat psychosis associated with Alzheimer's disease and Lewy body dementia. Currently, there is no FDA-approved drug specifically for the treatment of Alzheimer's disease psychosis.
